(FiveNation.com)- On Monday, President Biden marked the 60th anniversary of John F. Kennedy’s “moonshot” speech by traveling to Boston to announce his “Cancer Moonshot” initiative to reduce cancer deaths in the United States.
During a speech at the John F. Kennedy Presidential Library in Boston, Biden called for an end to “cancer as we know it” and vowed to reduce the cancer death rate by 50 percent in the next 25 years.
That day, Biden appointed Dr. Renee Wegrzyn to head up the Advanced Research Projects Agency for Health (ARPA-H), the agency that will oversee his “moonshot” initiative to speed government research into improving detection, prevention, and treatment for a range of diseases including cancer.
Biden also unveiled his executive order to boost domestic biotechnology and reduce US reliance on foreign biomanufacturing.
The president claimed the executive order will “ensure that America leads the world in biotechnology and biomanufacturing.” He also claimed that it would create jobs, strengthen supply chains, and reduce prices.
Then again, he also claimed the American Rescue Plan did not send inflation to 40-year highs.
Who believes that Joe Biden’s “moonshot” executive order will do anything to lower cancer deaths or create jobs?
In 2020, it was reported that Joe Biden’s cancer charity, the Biden Cancer Initiative, spent millions on salaries and absolutely nothing on cancer research. It’s safe to say any cancer initiative established under his presidency is unlikely to accomplish all the magical things old Joe says it will.
At the same event, Biden also boasted that the laughingly named Inflation Reduction Act was a “godsend” that will save people money on prescription drugs.
This, of course, is disputed.
Price controls notoriously do not work as intended, which is precisely why governments shouldn’t impose them.
What’s more, imposing price controls on prescription drugs will likely make Biden’s “cancer moonshot” backfire as drug companies will be forced to reduce the expense involved in the research and development of new cancer drugs.
